Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts. - Òdena A; Monserrat L; Brasó-Maristany F; García-Galea E; Casals E; Molina C; Herencia-Ropero A; Pedretti F; Domènech H; Guzmán M; Rodríguez O; Grueso J; et al. (NPJ precision oncology, 2025)